Is PPARγ a prospective player in HIV-1-associated bone disease?

Area of Science:

• Endocrinology
• Virology
• Bone Biology

Background:

• Human immunodeficiency virus-1 (HIV-1) infection is manageable with antiretroviral therapy (ART), but ART has toxicities.
• ART-associated toxicities include reduced bone mineral density (BMD) and fat metabolism disorders (lipodystrophy).
• Peroxisome proliferator-activated receptor gamma (PPARγ) is crucial for adipocyte development; its alterations are linked to HIV-1 lipodystrophy.

Purpose of the Study:

• To investigate the interdependence of reduced BMD and lipodystrophy in HIV-1 infection and treatment.
• To explore the hypothesis that PPARγ dysregulation contributes to both lipid and bone abnormalities in HIV-1.
• To review current knowledge and future directions regarding PPARγ's role in HIV-1-associated bone disease.

Main Methods:

• Review of existing literature on HIV-1, ART, PPARγ, bone metabolism, and fat metabolism.
• Analysis of the role of PPARγ in adipogenesis and osteoblastogenesis from common mesenchymal stem cells.
• Synthesis of evidence linking PPARγ dysregulation to bone abnormalities in HIV-1 infection.

Main Results:

• PPARγ plays a vital role in adipocyte development and is implicated in HIV-1-associated lipodystrophy.
• Adipocytes and osteoblasts share a common mesenchymal stem cell precursor, suggesting a potential link between fat and bone abnormalities.
• Dysregulation of PPARγ is hypothesized to underlie the bone abnormalities observed in HIV-1 infection and treatment.

Conclusions:

• PPARγ dysregulation is a potential unifying mechanism for both bone and fat abnormalities in HIV-1 patients.
• Further research into PPARγ's function is critical for understanding and potentially treating HIV-1-associated bone disease.
• Targeting PPARγ pathways may offer novel therapeutic strategies for managing ART-related complications.